← 返回

人参皂苷 Rh2 通过抑制 ERp5 增强乳腺癌中自然杀伤(NK)细胞的免疫监视

英文原题:Ginsenoside Rh2 enhances immune surveillance of natural killer (NK) cells via inhibition of ERp5 in breast cancer.

查看英文原题

Ginsenoside Rh2 enhances immune surveillance of natural killer (NK) cells via inhibition of ERp5 in breast cancer.

PubMed 2023/11/10(内容时间) Phytomedicine Q1 · IF 11.3(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

我们首次证实,GRh2 通过直接结合 ERp5 调控 NKG2D-MICA 信号轴,在增强 NK 细胞活性中发挥关键作用,并有望进一步优化为治疗乳腺癌的药物。

中文摘要

自然杀伤(NK)细胞参与抗肿瘤免疫应答,是阻止乳腺癌细胞形成远处转移的重要组成部分。人参的主要活性成分之一人参皂苷Rh2(GRh2)已用于癌症治疗,但其调节乳腺癌发展的作用仍不明确。

本研究旨在体内外剖析GRh2对乳腺癌的作用及其与NK细胞相关的潜在机制。

使用MDA-MB-231和4T1细胞建立原位及血行播散小鼠模型。分别将MDA-MB-231和MCF-7与NK92MI细胞或原代NK细胞进行体外共培养。通过免疫组织化学(IHC)、细胞计数试剂盒-8(CCK8)、肺部高分辨率微型计算机断层扫描(micro-CT)及苏木精-伊红(H&E)染色验证GRh2的抗肿瘤效力。采用乳酸脱氢酶(LDH)细胞毒性检测、流式细胞术、体内NK细胞清除、酶联免疫吸附试验(ELISA)、蛋白质印迹、定量逆转录聚合酶链反应(qRT-PCR)、免疫荧光和细胞转染研究GRh2的抗肿瘤机制。采用分子对接、微量热泳动(MST)和细胞热转移分析(CETSA)确定内质网蛋白5(ERp5)与GRh2的结合。

研究表明,GRh2通过增强NK细胞细胞毒功能,显著抑制乳腺癌生长和转移,表现为穿孔素、颗粒酶B和干扰素-(IFN-)释放增加。机制研究显示,GRh2能够降低ERp5表达,并且在MDA-MB-231细胞中及重组蛋白水平上直接结合ERp5。GRh2阻止可溶性MICA(sMICA)的形成,并在体内外上调MICA表达。重要的是,清除NK细胞后,GRh2降低乳腺癌肺转移的作用几乎完全消失。此外,GRh2能够直接嵌入ERp5结合口袋。

据我们所知,本研究首次证明GRh2可通过直接结合ERp5调节NKG2D-MICA信号轴,进而增强NK细胞活性;GRh2有望进一步优化为乳腺癌治疗药物。

展开英文摘要原文

One critical component of the immune system that prevents breast cancer cells from forming distant metastasis is natural killer (NK) cells participating in immune responses to tumors. Ginsenoside Rh2 (GRh2) as one of the major active ingredients of ginseng has been employed in treatment of cancers, but the function of GRh2 in modulating the development of breast cancer remains elusive.

This study was to dissect the effect of GRh2 against breast cancer and its potential mechanisms associated with NK cells, both in vitro and in vivo.

MDA-MB-231 and 4T1 cells were used to establish in situ and hematogenous mouse models. MDA-MB-231 and MCF-7 were respectively co-cultured with NK92MI cells or primary NK cells in vitro. Anti-tumor efficacy of GRh2 was verified by immunohistochemistry (IHC), Cell Counting Kit-8 (CCK8), high resolution micro-computed tomography (micro-CT) scanning of lungs and hematoxylin and eosin (H&E) staining. Lactate dehydrogenase (LDH) cytotoxicity assay, flow cytometry, in vivo depletion of NK cells, enzyme-linked immunosorbent assay (ELISA), western blot, quantitative reverse transcription polymerase chain reaction (qRT-PCR), immunofluorescence and cell transfection were performed for investigating the anti-tumor mechanisms of GRh2. Molecular docking, microscale thermophoresis (MST) and cellular thermal shift assay (CETSA) were employed to determine the binding between endoplasmic reticulum protein 5 (ERp5) and GRh2.

We demonstrated that GRh2 exerted prominent impacts on retarding the growth and metastasis of breast cancer through boosting the cytotoxic function of NK cells, as validated by the elevated release of perforin, granzyme B and interferon- (IFN- ). Mechanistical studies revealed that GRh2 was capable of diminishing the expression of ERp5 and GRh2 directly bound to ERp5 in MDA-MB-231 cells as well as on a recombinant protein level. GRh2 prevented the formation of soluble MICA (sMICA) and upregulated the expression level of MICA in vivo and in vitro. Importantly, the reduced lung metastasis of breast cancer by GRh2 was almost abolished upon the depletion of NK cells. Moreover, GRh2 was able to insert into the binding pocket of ERp5 directly.

We firstly demonstrated that GRh2 played a pivotal role in augmenting NK cell activity by virtue of modulating the NKG2D-MICA signaling axis via directly binding to ERp5, and may be further optimized to a therapeutic agent for the treatment of breast cancer.

论文信息

作者
Yang C、Qian C、Zheng W、Dong G、Zhang S、Wang F、Wei Z、Xu Y
第一作者单位
Department of Biochemistry and Molecular Biology, School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China; Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China.China
通讯作者单位
Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China; Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine (TCM) Prevention and Treatment of Tumor, Nanjing University of Chinese Medicine, Nanjing 210023, China. Electronic address: luyingreen@njucm.edu.cn.China
期刊
Phytomedicine : international journal of phytotherapy and phytopharmacology2024 Jan
原文标识
PubMed 38043385 · DOI 10.1016/j.phymed.2023.155180